RANKing c-Jun in osteoclast development.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 15314680.
- Also identified by PMC identifier 503777.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the <i>JCI</i> documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 .
Medical subject headings
- Carrier Proteins
- Membrane Glycoproteins
- NF-kappa B
- Nuclear Proteins
- Osteoclasts
- Proto-Oncogene Proteins c-jun